- Lantern Pharma ( NASDAQ: LTRN ) said the U.S. Food and Drug Administration (FDA) cleared the company to proceed with a phase 2 trial of LP-300 for never smoker patients with advanced non-small cell lung cancer (NSCLC).
- The study, dubbed Harmonic, will include 90 patients of which about 2/3 patients will receive LP-300 in combination with chemotherapy, while 1/3rd will receive chemotherapy alone.
- The company expects enrollment to occur over the next 12 to 16 months across multiple sites in the U.S.
- The company noted that in a previous phase 3 study, a subset of never smoker patients with NSCLC receiving LP-300 with chemotherapy showed increased overall and two-year survival of 91% and 125%, respectively, compared to patients on chemotherapy alone.
- LTRN +2.88% to $6.08 premarket July 14
For further details see:
Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer